In the scholarly communications environment, the evolution of a journal article can be traced by the relationships it has with its preprints. Those preprint–journal article relationships are an important component of the research nexus. Some of those relationships are provided by Crossref members (including publishers, universities, research groups, funders, etc.) when they deposit metadata with Crossref, but we know that a significant number of them are missing. To fill this gap, we developed a new automated strategy for discovering relationships between preprints and journal articles and applied it to all the preprints in the Crossref database. We made the resulting dataset, containing both publisher-asserted and automatically discovered relationships, publicly available for anyone to analyse.
The second half of 2023 brought with itself a couple of big life changes for me: not only did I move to the Netherlands from India, I also started a new and exciting job at Crossref as the newest Community Engagement Manager. In this role, I am a part of the Community Engagement and Communications team, and my key responsibility is to engage with the global community of scholarly editors, publishers, and editorial organisations to develop sustained programs that help editors to leverage rich metadata.
STM, DataCite, and Crossref are pleased to announce an updated joint statement on research data.
In 2012, DataCite and STM drafted an initial joint statement on the linkability and citability of research data. With nearly 10 million data citations tracked, thousands of repositories adopting data citation best practices, thousands of journals adopting data policies, data availability statements and establishing persistent links between articles and datasets, and the introduction of data policies by an increasing number of funders, there has been significant progress since.
Have you attended any of our annual meeting sessions this year? Ah, yes – there were many in this conference-style event. I, as many of my colleagues, attended them all because it is so great to connect with our global community, and hear your thoughts on the developments at Crossref, and the stories you share.
Let me offer some highlights from the event and a reflection on some emergent themes of the day.
It’s here. After years of hard work and with a huge cast of characters involved, I am delighted to announce that you will now be able to instantly link to all published articles related to an individual clinical trial through the Crossmark dialogue box. Linked Clinical Trials are here!
In practice, this means that anyone reading an article will be able to pull a list of both clinical trials relating to that article and all other articles related to those clinical trials – be it the protocol, statistical analysis plan, results articles or others – all at the click of a button.
Linked Clinical Trials interface
Now I’m sure you’ll agree that this sounds nifty. It’s definitely a ‘nice-to-have’. But why was it worth all the effort? Well, simply put: “to move a mountain, you begin by carrying away the small stones”.
Science communication in its current form is an anachronism, or at the very least somewhat redundant.
You may have read about the ‘crisis in reproducibility’. Good science, at its heart, should be testable, falsifiable and reproducible, but an historical over-emphasis on results has led to a huge number of problems that seriously undermine the integrity of the scientific literature.
This is, of course, nothing new. Calls for prospective registration of clinical trials date back to the 1980s and it is now becoming increasingly commonplace, recognising that the quality of research lies in the questions it asks and the methods it uses, not the results observed.
Uptake of trial registration year-on-year since 2000
Building on this, a number of journals and funders – starting with BioMed Central’s Trialsover 10 years ago – have also pushed for the prospective publication of a study’s protocol and, more recently, statistical analysis plan. The idea that null and non-confirmatory results have value and should be published has also gained increasing support.
Over the last ten years, there has been a general trend towards increasing transparency. So what is the problem? Well, to borrow an analogy from Jeremy Grimshaw, co-Editor-in-Chief of Trials – we’ve gone from Miró to Pollock.
Although a results paper may reference a published study protocol, there is nothing to link that report to subsequent published articles; and no link from the protocol itself to the results article.
A single clinical trial can result in multiple publications: the study protocol and traditional results paper or papers, as well as commentaries, secondary analyses and, eventually, systematic reviews, among others, many published in different journals, years apart. This situation is further complicated by an ever-growing body of literature.
Researchers need access to all of these articles if they are to reliably evaluate bias or selective reporting in a research object, but – as any systematic reviewer can tell you – actually finding them all is like looking for a needle in a haystack. When you don’t know how many needles there are. With the haystack still growing.
That’s where we come in. The advent of trial registration means that there is a unique identifier associated with every clinical trial, at the study-level, rather than the article level. Building on this, the Linked Clinical Trials project set out to connect all articles relating to an individual trial together using its trial registration number (TRN).
By adapting the existing Crossmark standard, we have captured additional metadata about an article, namely the TRN and the trial registry, with this information then associated with the article’s DOI on publication. This means that you will be able to pull all articles related to an individual clinical trial from the Crossmark dialogue box on any relevant article.
This obviously has huge implications for the way science is reported and used. By quickly and easily linking to related published articles, it will enable editors, reviewers and researchers to evaluate any selective reporting in the study, and help to provide far greater context for the results.
As all the metadata will be open access (CC0), with no copyright, it will also be possible to access this article ‘thread’ through the Crossref Metadata Search, or independently through an application programming interface (API). This provides a platform for others to build on, with many already looking to take the next step, such as Ben Goldacre’s new Open Trials initiative.
However, in order for this to work, we must capture as many articles and trials as possible to create a truly comprehensive thread of publications. We currently have data from the NIHR Libraries, PLoS and, of course, BioMed Central, but need more publishers and journals to join us in depositing clinical trial metadata. After all, without metadata, this is all merely wishful thinking.
Let’s hope we’re the pebble that starts the landslide.